| Autor: |
Yousaf, M., Ayasse, M., Ahmed, A., Gwillim, E.C., Janmohamed, S.R., Yousaf, A., Patel, K.R., Thyssen, J.P., Silverberg, J.I. |
| Předmět: |
|
| Zdroj: |
British Journal of Dermatology; Feb2022, Vol. 186 Issue 2, p227-235, 9p |
| Abstrakt: |
Summary: Background: Previous studies have found conflicting results about the association of atopic dermatitis (AD) with hypertension. Objectives: To determine whether AD and AD severity are associated with hypertension. Methods: A systematic review was performed of published studies in Ovid MEDLINE, Embase, Scopus, Web of Science, and GREAT (Global Resource for EczemA Trials) databases. At least two reviewers conducted title/abstract, full‐text review and data extraction. Quality of evidence was assessed using the Newcastle–Ottawa Scale. Results: Fifty‐one studies met the inclusion criteria and 19 had sufficient data for meta‐analysis. AD was associated with higher odds of hypertension compared with healthy controls [increased in nine of 16 studies; pooled prevalence 16·4% vs. 13·8%; random‐effects regression, pooled unadjusted odds ratio (OR) 1·16, 95% confidence interval (CI) 1·04–1·30], but lower odds of hypertension compared with psoriasis [decreased in five of eight studies; 15·4% vs. 24·8% (OR 0·53, 95% CI 0·37–0·76)]. In particular, moderate‐to‐severe AD was associated with hypertension compared with healthy controls [increased in four of six studies; 24·9% vs. 14·7% (OR 2·33, 95% CI 1·10–4·94)]. Hypertension was commonly reported as an adverse event secondary to AD treatments, particularly systemic ciclosporin A. Limitations include lack of longitudinal studies or individual‐level data, and potential confounding. Conclusions: AD, particularly moderate‐to‐severe disease, was associated with increased hypertension compared with healthy controls, but with lower odds than for psoriasis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text